TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07866105: A Phase 2b, Randomized, Double-Blind, Vehicle-Controlled Multi-Center Study of the Efficacy, Safety, and Tolerability of B244 Delivered as a Topical Spray in the Treatment of Moderate to Severe Acne Vulgaris

Sponsor: AOBiome LLC · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 176 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,256,000

Rescue Site Savings

+$5,443,800

Unlock Full NCT07866105 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07866105 Rescue Dossier →